Navigation Links
Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
Date:12/22/2011

SAN DIEGO, Dec. 22, 2011 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the completion of its public offering of 5,646,173 units.  Each unit consisted of one share of common stock and a warrant to purchase ten shares of common stock, at a price to the public of $1.45 per share of common stock and $1.449 per warrant to purchase each share of common stock, which together comprised the purchase price of $15.94 per unit.   Net proceeds, after underwriting discounts and commissions and estimated expenses, were approximately $86.9 million.  The underwriter does not have an option to purchase any additional units in this offering. Leerink Swann LLC acted as sole manager for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 17, 2009.  The offering was made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained from Leerink Swann LLC , Attention: Syndicate Department, One Federal Street, 37th Fl., Boston, MA 02110 or by calling Leerink Swann LLC, toll free, at 1-800-808-7525, Ext. 4814.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Orexigen® Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave® has completed Phase 3 clinical trials, and the Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

 

 

 


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Orexigen® Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
2. Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
3. Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
4. Orexigen® Therapeutics Provides a Regulatory Update on Contrave® NDA
5. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
6. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
7. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
8. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
11. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... CHESTERBROOK, Pa., Oct. 30, 2014   Auxilium ... a fully integrated specialty biopharmaceutical company, today announced ... 30, 2014. The Company highlighted important corporate, commercial, ... "We are very pleased with ... core growth products in our portfolio this quarter, ...
(Date:10/30/2014)... 2014 , Extensively hydrolyzed milk ...   Cow milk protein allergy (CMPA) is the leading cause ... now, it has been managed by eliminating milk proteins ... that it is possible to help build of oral ... children during the first year of life by using ...
(Date:10/30/2014)... 2014 nebulizer is a medical device used ... cystic fibrosis) that converts liquid medication into mist or ... lungs of a patient when inhaled through the mouth ... dominated by various devices powered by electric current and ... COPD and cystic fibrosis and growing number of geriatric ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3
... 12, 2007 /PRNewswire-FirstCall/ --,InB:Biotechnologies, Inc. ("BioTech"), a ... announced strong positive,results in studies of vaccines ... novel, proprietary AIPwLV(TM) vaccine technology. The,studies were ... Molecular,Biotechnology (CMB), the Contract Research Organization led ...
... LUND, Sweden, March 13, 2007--Active Biotech AB,(Stockholm:ACTI.ST) ... a first human micro-dosing trial of an,I-3D ... was to determine the pharmacokinetic,characteristics of the ... healthy volunteers. , The study demonstrated that ...
Cached Medicine Technology:Integrated Biopharma's Proprietary Vaccine Technology Achieves,Strong Positive Results 2Active Biotech's I-3D Micro-dosing Clinical Trial Concluded 2
(Date:10/30/2014)... 2014 Graphics, coding, typography and search ... the craft of web design and require thorough knowledge ... simpler solution to create a website can be as ... information, customer reviews and Facebook posts all accumulate on ... the next evolution of how a business can develop ...
(Date:10/30/2014)... 30, 2014 PreDiabetes Centers , ... Store shoppers with a supply of sugardown®, a ... reduce post-meal blood sugar spikes. Learning how to control ... important part of a diabetes prevention plan. , Shoppers ... one complimentary tube of sugardown. The offer expires November ...
(Date:10/30/2014)... Tara Haelle HealthDay Reporter ... More than 100 genes have been identified that appear ... And researchers say they are on their way ... contribute to the disorder. Autism spectrum disorders include ... social difficulties and repetitive behaviors. An estimated one in ...
(Date:10/30/2014)... 30, 2014 Horse Sense & ... riding to special needs individuals in the Jacksonville area, ... November 15 from 10-2:00 p.m. at Bailey's Farm (2202 ... to the public and is designed to raise awareness ... to the HSS Round-Up is free. Ticket purchases will ...
(Date:10/30/2014)... Hill, South Carolina (PRWEB) October 30, 2014 ... muscle, and should be more vigorously exercised to help ... He recently authored the book ‘Dementia Express: Lose Your ... The book uses counterintuitive reasoning and sometimes conflicting attitudes ... obstacle course for the mind, a reader must decipher ...
Breaking Medicine News(10 mins):Health News:Facebook Websites In Thirty-Seconds 2Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2
... April 24 International SOS has launched a new ... flu outbreak to members of the public and the ... t ionalsos.com , provides updates on the ... that those in California, Texas and Mexico, or traveling ...
... from a telemedicine device company to that of a Telemedicine Encounter ... ... (PRWEB) April 24, 2009 -- AMD Global Telemedicine, Inc., announces the ... AMD will showcase its new end to end clinical telemedicine ...
... in real time during transportSCOTTSDALE, Ariz., April 24 ... GlobalMedia, an innovator of video imaging and visual ... announced today that it will unveil the newest ... the American Telemedicine Association (ATA) Annual Meeting and ...
... DETROIT, April 24, United American Healthcare Corporation (Nasdaq: ... management services to a managed care organization in Tennessee, ... the third fiscal quarter ended March 31, 2009 on ... Company will host a conference call at 4:30 p.m. ...
... intensity-modulated radiotherapy (IMRT), RapidArc(TM) radiotherapy, and stereotactic ... Varian Medical Systems (NYSE: ... spectrum of prostate cancer treatment technologies at ... at McCormick Place in Chicago from April ...
... dying, researchers report , , FRIDAY, April 24 (HealthDay News) ... fibrillation after heart bypass surgery are at increased long-term ... report sounds a warning bell for doctors about an ... concern, said Giovanni Filardo, director of the department of ...
Cached Medicine News:Health News:International SOS Releases Web Site to Educate Public About Swine Flu Outbreak 2Health News:AMD Global Telemedicine Inc. to Unveil New Solutions at ATA 2009 Conference in Las Vegas 2Health News:GlobalMedia Launches Telemedicine Product for Ambulatory and Emergency Care 2Health News:GlobalMedia Launches Telemedicine Product for Ambulatory and Emergency Care 3Health News:GlobalMedia Launches Telemedicine Product for Ambulatory and Emergency Care 4Health News:United American Healthcare Corporation to Host Fiscal 2009 Third Quarter Results Conference Call May 7th 2Health News:Varian Medical Systems to Exhibit Full Spectrum of Prostate Cancer Treatment Technologies at the American Urological Association Meeting in Chicago 2Health News:Varian Medical Systems to Exhibit Full Spectrum of Prostate Cancer Treatment Technologies at the American Urological Association Meeting in Chicago 3Health News:Varian Medical Systems to Exhibit Full Spectrum of Prostate Cancer Treatment Technologies at the American Urological Association Meeting in Chicago 4Health News:Abnormal Heartbeat After Bypass a Bad Sign 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: